Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

131 trials with published results (15%)

Research Maturity

668 completed trials (78% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.5%

30 terminated out of 859 trials

Success Rate

95.7%

+9.2% vs benchmark

Late-Stage Pipeline

27%

231 trials in Phase 3/4

Results Transparency

20%

131 of 668 completed with results

Key Signals

131 with results96% success30 terminated

Data Visualizations

Phase Distribution

718Total
Not Applicable (193)
Early P 1 (3)
P 1 (198)
P 2 (93)
P 3 (108)
P 4 (123)

Trial Status

Completed668
Unknown81
Terminated30
Recruiting24
Withdrawn23
Active Not Recruiting20

Trial Success Rate

95.7%

Benchmark: 86.5%

Based on 668 completed trials

Clinical Trials (859)

Showing 20 of 20 trials
NCT06607003Phase 1RecruitingPrimary

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT05652504Phase 1SuspendedPrimary

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

NCT06069544Phase 1CompletedPrimary

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT03937817Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT06735209Phase 1Active Not RecruitingPrimary

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT04978272Phase 3Active Not RecruitingPrimary

Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)

NCT07208760Phase 2WithdrawnPrimary

L9LS-R21 Interaction

NCT01168271RecruitingPrimary

Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali

NCT05155579Phase 1CompletedPrimary

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

NCT02639299RecruitingPrimary

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

NCT04650815CompletedPrimary

Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso

NCT05796193Not ApplicableActive Not RecruitingPrimary

Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire

NCT03719599CompletedPrimary

Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia

NCT07194668Phase 4Not Yet Recruiting

R21/MM Dosing, Presentations, and Preservatives

NCT00001645RecruitingPrimary

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

NCT07470424Phase 1Not Yet RecruitingPrimary

A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults

NCT06468319RecruitingPrimary

Pregnancy Registry in Mali

NCT07468526Phase 3Not Yet RecruitingPrimary

An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

NCT03855995CompletedPrimary

A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa

NCT07430592Phase 2Not Yet RecruitingPrimary

This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

Scroll to load more

Research Network

Activity Timeline